MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 31, 2007; DOI: 10.1124/mol.107.039800


0026-895X/08/7303-813-823$20.00
Mol Pharmacol 73:813-823, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.039800v1
73/3/813    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MolPharm
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loland, C. J.
Right arrow Articles by Gether, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loland, C. J.
Right arrow Articles by Gether, U.

Relationship between Conformational Changes in the Dopamine Transporter and Cocaine-Like Subjective Effects of Uptake Inhibitors

Claus J. Loland, Rajeev I. Desai, Mu-Fa Zou, Jianjing Cao, Peter Grundt, Klaus Gerstbrein, Harald H. Sitte, Amy Hauck Newman, Jonathan L. Katz, and Ulrik Gether

Molecular Neuropharmacology Group, Department of Neuroscience and Pharmacology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark (C.J.L., U.G.); Psychobiology (R.I.D., J.L.K.) and Medicinal Chemistry Sections (M.-F.Z., J.C., P.G., A.H.N.), Medications Discovery Research Branch, Intramural Research Program, Department of Health and Human Services, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland; and Institute for Pharmacology, Center for Biomolecular Medicine and Pharmacology, Medical University Vienna, Vienna, Austria (K.G., H.H.S.)

Cocaine exerts its stimulatory effect by inhibiting the dopamine transporter (DAT). However, novel benztropine- and rimcazole-based inhibitors show reduced stimulant effects compared with cocaine, despite higher affinity and selectivity for DAT. To investigate possible mechanisms, we compared the subjective effects of different inhibitors with their molecular mode of interaction at the DAT. We determined how different inhibitors affected accessibility of the sulfhydryl-reactive reagent [2-(trimethylammonium)ethyl]-methanethiosulfonate to an inserted cysteine (I159C), which is accessible when the extracellular transporter gate is open but inaccessible when it is closed. The data indicated that cocaine analogs bind an open conformation, whereas benztropine and rimcazole analogs bind a closed conformation. Next, we investigated the changes in inhibition potency of [3H]dopamine uptake of the compounds at a mutant DAT (Y335A) characterized by a global change in the conformational equilibrium. We observed a close relationship between the decrease in potencies of inhibitors at this mutant and cocaine-like responding in rats trained to discriminate cocaine from saline injections. Our data suggest that chemically different DAT inhibitors stabilize distinct transporter conformations and that this in turn affects the cocaine-like subjective effects of these compounds in vivo.


Received July 13, 2007; accepted October 31, 2007

Address correspondence to: Dr. Claus J. Loland, Molecular Neuropharmacology Group, Department of Neuroscience and Pharmacology, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark. E-mail: claus{at}neuropharm.ku.dk


Related articles in MolPharm:

Distinctions between Dopamine Transporter Antagonists Could be Just around the Bend
L. Keith Henry and Randy D. Blakely
MolPharm 2008 73: 616-618. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
K. L. Nicholson, R. L. Balster, K. Golembiowska, M. Kowalska, J. P. Tizzano, P. Skolnick, and A. S. Basile
Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 236 - 248.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Hiranita, P. L. Soto, A. H. Newman, and J. L. Katz
Assessment of Reinforcing Effects of Benztropine Analogs and Their Effects on Cocaine Self-Administration in Rats: Comparisons with Monoamine Uptake Inhibitors
J. Pharmacol. Exp. Ther., May 1, 2009; 329(2): 677 - 686.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
L. K. Henry and R. D. Blakely
Distinctions between Dopamine Transporter Antagonists Could be Just around the Bend
Mol. Pharmacol., March 1, 2008; 73(3): 616 - 618.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics